| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
10,510,000 |
| Market
Cap: |
30.74(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.125 - $4.83 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Protara Therapeutics is a clinical-stage biopharmaceutical company focused on identifying and developing transformative therapies for the treatment of cancer and rare diseases. Co.'s primary oncology program is TARA-002 in non-muscle invasive bladder cancer. Co. is also pursuing TARA-002 in lymphatic malformations, which are rare, non-malignant cysts of the lymphatic vascular system. The third development program in Co.'s portfolio is intravenous Choline Chloride, an investigational phospholipid substrate replacement therapy initially in development for patients receiving parenteral nutrition, who have intestinal failure associated liver disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
42,965 |
| Total Buy Value |
$0 |
$0 |
$0 |
$159,618 |
| Total People Bought |
0 |
0 |
0 |
3 |
| Total Buy Transactions |
0 |
0 |
0 |
4 |
| Total Shares Sold |
0 |
0 |
0 |
15,473 |
| Total Sell Value |
$0 |
$0 |
$0 |
$41,949 |
| Total People Sold |
0 |
0 |
0 |
1 |
| Total Sell Transactions |
0 |
0 |
0 |
1 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bandari Jathin |
Chief Medical Officer |
• – – |
2024-01-19 |
4 |
D |
$1.91 |
$5,499 |
D/D |
(2,879) |
56,704 |
|
- |
|
| Bandari Jathin |
Chief Medical Officer |
• – – |
2024-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
23,000 |
59,583 |
|
- |
|
| Fabbio Patrick |
Chief Financial Officer |
• – – |
2024-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
22,000 |
22,000 |
|
- |
|
| Zummo Jacqueline |
Chf Scientific Operations Off |
• – – |
2024-01-19 |
4 |
D |
$1.91 |
$5,824 |
D/D |
(3,049) |
104,296 |
|
- |
|
| Zummo Jacqueline |
Chf Scientific Operations Off |
• – – |
2024-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
23,000 |
107,345 |
|
- |
|
| Fry Hannah |
VP, Controller |
• – – |
2024-01-19 |
4 |
D |
$1.91 |
$1,727 |
D/D |
(904) |
29,836 |
|
- |
|
| Fry Hannah |
VP, Controller |
• – – |
2024-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
30,740 |
|
- |
|
| Shefferman Jesse |
CEO and President |
• • – |
2024-01-19 |
4 |
D |
$1.91 |
$14,904 |
D/D |
(7,803) |
944,064 |
|
- |
|
| Shefferman Jesse |
CEO and President |
• • – |
2024-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
59,000 |
951,867 |
|
- |
|
| Zummo Jacqueline |
Chf Scientific Operations Off |
• – – |
2024-01-10 |
4 |
D |
$2.39 |
$12,497 |
D/D |
(5,229) |
84,345 |
|
- |
|
| Shefferman Jesse |
CEO and President |
• • – |
2024-01-10 |
4 |
D |
$2.39 |
$13,733 |
D/D |
(5,746) |
892,867 |
|
- |
|
| Bandari Jathin |
Chief Medical Officer |
• – – |
2024-01-10 |
4 |
D |
$2.39 |
$4,486 |
D/D |
(1,877) |
36,583 |
|
- |
|
| Shefferman Jesse |
CEO and President |
• • – |
2024-01-03 |
4 |
D |
$2.17 |
$12,673 |
D/D |
(5,840) |
898,613 |
|
- |
|
| Fry Hannah |
VP, Controller |
• – – |
2024-01-03 |
4 |
D |
$2.17 |
$703 |
D/D |
(324) |
22,740 |
|
- |
|
| Zummo Jacqueline |
Chf Scientific Operations Off |
• – – |
2024-01-03 |
4 |
D |
$2.17 |
$4,121 |
D/D |
(1,899) |
89,574 |
|
- |
|
| Fry Hannah |
VP, Controller |
• – – |
2023-07-17 |
4 |
D |
$2.56 |
$25,792 |
D/D |
(10,075) |
23,064 |
|
- |
|
| Bandari Jathin |
Chief Medical Officer |
• – – |
2023-07-03 |
4 |
D |
$2.46 |
$1,678 |
D/D |
(682) |
38,460 |
|
- |
|
| Shefferman Jesse |
CEO and President |
• • – |
2023-06-27 |
4 |
GD |
$0.00 |
$0 |
D/D |
7,420 |
904,453 |
|
- |
|
| Shefferman Jesse |
CEO and President |
• • – |
2023-06-23 |
4 |
GD |
$0.00 |
$0 |
D/D |
1,890 |
911,873 |
|
- |
|
| Fry Hannah |
VP, Controller |
• – – |
2023-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
5,900 |
33,139 |
|
- |
|
| Zummo Jacqueline |
Chf Scientific Operations Off |
• – – |
2023-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
19,900 |
91,473 |
|
- |
|
| Shefferman Jesse |
CEO and President |
• • – |
2023-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
51,300 |
918,282 |
|
- |
|
| Bandari Jathin |
Chief Medical Officer |
• – – |
2023-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
20,700 |
39,142 |
|
- |
|
| Shefferman Jesse |
CEO and President |
• • – |
2023-01-10 |
4 |
D |
$3.00 |
$17,565 |
D/D |
(5,855) |
866,982 |
|
- |
|
| Bandari Jathin |
Chief Medical Officer |
• – – |
2023-01-10 |
4 |
D |
$3.00 |
$5,628 |
D/D |
(1,876) |
18,442 |
|
- |
|
196 Records found
|
|
Page 1 of 8 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.13 (4.1%) 
